Ultraviolet Light Slated for Review as Carcinogen

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

RESEARCH TRIANGLE PARK, NC-The National Toxicology Program (NTP) plans to review the three wavelength groups of ultraviolet light-UVA, UVB, and UVC-for possible listing in the federal government’s Tenth Annual Report on Carcinogens. The three wavelengths occur in varying amounts in sunlight and in some forms of artificial light, such as that used in sun lamps and tanning beds.

 RESEARCH TRIANGLE PARK, NC—The National Toxicology Program (NTP) plans to review the three wavelength groups of ultraviolet light—UVA, UVB, and UVC—for possible listing in the federal government’s Tenth Annual Report on Carcinogens. The three wavelengths occur in varying amounts in sunlight and in some forms of artificial light, such as that used in sun lamps and tanning beds.

Multilayered reviews are done to determine if a suspected carcinogen should be designated as a known human carcinogen or as reasonably anticipated to be a human carcinogen. The first review is done by scientists at the National Institute of Environmental Health Sciences and a second by scientists from a number of federal agencies. Finally, a panel of outside experts examines the data in a public hearing.

Among other substances being considered for listing:

The fire retardants 2,2-bis-bromo-methylpropanediol and 2,3-dibromo-1-propanol.

Vinyl bromide, which is used in making flame-retardant synthetic fibers.

Vinyl fluoride, used in producing plastics.

Two classes of dyes—the dimeth-oxybenzidines and dimethylbenzidines—used in textiles, leather, plastics, paper, and rubber.

 Styrene-7,8-oxide, used in preparing fragrances and in some epoxy resins.

 IQ, a compound found in cooked meat and fish.

In addition, beryllium and beryllium compounds, currently on the reasonably anticipated list, will be reviewed for possible upgrading to known human carcinogens.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content